KEYTRUDA potentiates T-cell responses, including antitumor responses, by blocking PD-1 binding to PD-L1 and PD-L2, which are expressed on antigen-presenting cells and may be expressed by tumors or other cells in the tumor microenvironment [18]. Here, CD274 is linked to neoplasm.